Form 4: Conduit Pharmaceuticals Director Acquires Shares in Lieu of Cash Retainer

Chele Chiavacci Farley, a director of Conduit Pharmaceuticals, acquired 32,022 shares of common stock in lieu of $28,500 in cash retainers.

Summary

• On March 30, 2025, Chele Chiavacci Farley, a director of Conduit Pharmaceuticals Inc. [CDT], acquired 32,022 shares of common stock.
• The shares were acquired at a price of $0.89 per share.
• This acquisition was made in lieu of $28,500 accrued in cash retainers under the Issuer's Non-Employee Director Compensation Program, pursuant to the 2023 Stock Incentive Plan.
• Following the transaction, Farley directly owns 35,537 shares of Conduit Pharmaceuticals.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transaction is part of a pre-existing compensation plan and doesn't necessarily indicate a significant change in the company's outlook.

Positives

• A director's decision to take shares in lieu of cash may signal confidence in the company's future prospects.

Industry Context

Directors receiving stock in lieu of cash compensation is a fairly common practice, especially for smaller companies, as it can help conserve cash and align the interests of directors with those of shareholders.

Related Party Transactions

• The issuance of shares to Chele Chiavacci Farley, a director, in lieu of cash retainers is a related party transaction.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it slightly dilutes existing ownership.

Key Dates

Keywords

Conduit Pharmaceuticals, Director, Share Acquisition, Stock Incentive Plan, Form 4, Beneficial Ownership, CDT